IDO1 and non-small cell lung carcinoma: This could lead to set up a multidisciplinary diagnostic workflow that would allow the early histopathological identification of NSCLC patients with adenocarcinoma, to specifically determine their serum Kyn/Trp ratio and identify the lung cancers which could benefit from therapies targeting the IDO1-kynurenine pathway axis.